Axitinib is a highly selective inhibitor of vascular endothelial growth factor receptor (VEGFR) tyrosine kinases 1–3 by blocking downstream signaling through Akt and extracellular signal-regulated kinase (ERK) in renal cell carcinoma (RCC) [1]. Here, KDR is linked to renal cell carcinoma.